Figure 5.
Effect of Erb-hcAb and trastuzumab on tumour growth of JIMT-1 (A) and KPL-4 (B) xenografts. On day 7, when tumours were clearly detectable, mice were randomised (10 per group) to receive the following treatments: intraperitoneal (i.p.) trastuzumab (3.75 mg kg−1, twice a week for 3 weeks) or i.p. Erb-hcAb (2.5 mg kg−1, twice a week for 3 weeks). Control animals were treated with sterile phosphate-buffered saline solution. Student's t-test was used to compare tumour sizes among different treatment groups. Bars, s.d.